重组融合蛋白ESAT6-CPF10皮肤试验在大型人群中的安全性与诊断性能:4期临床试验
该研究在社区≥6月龄人群中分两阶段评估重组融合蛋白EC皮肤试验(ECST):第一阶段随机双盲对照(n=500)比较ECST与TST的诊断性能,第二阶段非随机开放(n=7000)评估安全性。结果显示ECST敏感性89.41%、特异性96.98%,与T-SPOT.TB一致性κ=0.85;不良反应发生率11.75%,≥3级0.67%。
要点
- ECST敏感性89.41%、特异性96.98%,与T-SPOT.TB一致性κ=0.85。
- TST特异性仅61.06%,与T-SPOT.TB一致性κ=0.28。
- 总体不良反应发生率11.75%,≥3级0.67%,随年龄增长升高。
核心结论
- ECST在≥6月龄社区人群中具有满意的安全性和诊断性能,适合用于结核分枝杆菌感染筛查。
研究设计与样本
- 两阶段社区人群试验:第一阶段随机双盲对照设计(n=500),第二阶段非随机开放设计(n=7000)。
主要发现
- 第一阶段ECST敏感性89.41%(95%CI 80.85%-95.04%),TST敏感性85.88%(95%CI 76.64%-92.49%)。
- 第一阶段ECST特异性96.98%(95%CI 94.79%-98.43%),TST特异性61.06%(95%CI 56.07%-65.87%)。
- ECST与T-SPOT.TB一致性κ=0.85,高于TST与T-SPOT.TB的κ=0.28。
- 第二阶段不良反应发生率11.75%,≥3级0.67%;<18岁2.89%,18-64岁11.51%,≥65岁16.98%。
- 肺结核患者不良反应发生率46.58%,HIV感染者33.33%,糖尿病患者15.56%,结核患者密切接触者14.35%,有过敏史者11.93%。
临床怎么用
- ECST可用于社区≥6月龄人群的结核分枝杆菌感染筛查,特异性优于TST。
- 高龄、肺结核、HIV感染、糖尿病、结核密切接触及过敏史人群不良反应发生率较高,接种后需关注。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: This study aimed to evaluate the safety and diagnostic performance of recombinant fusion protein early secretory antigenic target protein 6-culture filtrate protein 10 (EC) in a community-based population aged ≥6 months. METHODS: We conducted a 2-stage trial in a community-based population. The first stage used a randomized, double-blind, controlled design (n = 500), while the second stage used a nonrandomized, open design (n = 7000). Stage 1 participants underwent tuberculosis-specific enzyme-linked immunospot assay (T-SPOT.TB), tuberculin skin test (TST), and EC skin test (ECST). Stage 2 participants only received the ECST. The purposes of the first and second stage were to evaluate the diagnostic performance and safety of the ECST, respectively. RESULTS: At the first stage, the sensitivity of ECST and TST was 89.41% (95% confidence interval [CI], 80.85%-95.04%) and 85.88% (95% CI, 76.64%-92.49%), respectively. The specificity of the ECST and TST was 96.98% (95% CI, 94.79%-98.43%%) and 61.06% (95% CI, 56.07%-65.87%), respectively. The consistency between ECST and T-SPOT.TB was higher than that between TST and T-SPOT.TB (κ = 0.85 and 0.28, respectively). At the second stage, the incidence of adverse drug reactions (ADRs) was 11.75%, with 0.67% graded ≥3. The incidence of ADRs varied among age groups (<18 years, 2.89%; 18-64 years, 11.51%; ≥65 years, 16.98%) and was significantly higher in individuals with pulmonary tuberculosis (46.58%), human immunodeficiency virus infection (33.33%), diabetes mellitus (15.56%), close contacts of patients with tuberculosis (14.35%), and those with allergic histories (11.93%). CONCLUSIONS: ECST has a satisfactory safety and diagnostic performance profile and is suitable for screening Mycobacterium tuberculosis infection in the community-based population aged ≥6 months. Clinical Trials Registration. NCT05746611.
引用
- Chen J, Zhao L, Zhou X, et al. Safety and Diagnostic Performance of Recombinant Fusion Protein ESAT6-CPF10 Skin Test in A Large Population: A Phase 4 Clinical Trial. J Infect Dis. 2025. PMID: 40560769. doi:10.1093/infdis/jiaf332
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。